Cargando…
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia
BACKGROUND: Acute myeloid leukemia (AML) is an incurable disease with fatal infections or relapse being the main causes of death in most cases. In particular, the severe infections occurring in these patients before or during any treatment suggest an intrinsic alteration of the immune system. In thi...
Autores principales: | Musuraca, Gerardo, De Matteis, Serena, Napolitano, Roberta, Papayannidis, Cristina, Guadagnuolo, Viviana, Fabbri, Francesco, Cangini, Delia, Ceccolini, Michela, Giannini, Maria Benedetta, Lucchesi, Alessandro, Ronconi, Sonia, Mariotti, Paolo, Savini, Paolo, Tani, Monica, Fattori, Pier Paolo, Guidoboni, Massimo, Martinelli, Giovanni, Zoli, Wainer, Amadori, Dino, Carloni, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502949/ https://www.ncbi.nlm.nih.gov/pubmed/26174551 http://dx.doi.org/10.1186/s12967-015-0590-1 |
Ejemplares similares
-
PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
por: Cerchione, C., et al.
Publicado: (2022) -
PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
por: Cerchione, C., et al.
Publicado: (2022) -
PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022) -
PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
por: Cerchione, C., et al.
Publicado: (2022) -
Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?
por: Lucchesi, Alessandro, et al.
Publicado: (2019)